Search Result

Results for "

epithelial cancers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (15) Autophagy (2) Bcl-2 Family (4) Biochemical Assay Reagents (1) c-Myc (1) CD3 (2) CDK (1) COX (2) Cytochrome P450 (1) EBV (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) FAK (1) Ferroptosis (2) FGFR (1) FLT3 (1) GABA Receptor (1) Glucosylceramide Synthase (GCS) (1) GnRH Receptor (2) HSP (1) JNK (1) MAP4K (2) NF-κB (1) PDGFR (1) Phosphatase (1) PI3K (1) Prostaglandin Receptor (1) Pyroptosis (1) Reactive Oxygen Species (1) STAT (3) TAM Receptor (1) TGF-beta/Smad (1) TrxR (1) Wnt (3)
By Research Areas:	Cancer (44) Endocrinology (2) Inflammation/Immunology (4)

By Targets:

Akt (1)

Apoptosis (15)

Autophagy (2)

Bcl-2 Family (4)

Biochemical Assay Reagents (1)

c-Myc (1)

CD3 (2)

CDK (1)

COX (2)

Cytochrome P450 (1)

EBV (1)

EGFR (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

FAK (1)

Ferroptosis (2)

FGFR (1)

FLT3 (1)

GABA Receptor (1)

Glucosylceramide Synthase (GCS) (1)

GnRH Receptor (2)

HSP (1)

JNK (1)

MAP4K (2)

NF-κB (1)

PDGFR (1)

Phosphatase (1)

PI3K (1)

Prostaglandin Receptor (1)

Pyroptosis (1)

Reactive Oxygen Species (1)

STAT (3)

TAM Receptor (1)

TGF-beta/Smad (1)

TrxR (1)

Wnt (3)

By Research Areas:

Cancer (44)

Endocrinology (2)

Inflammation/Immunology (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-N2080

Songorine	GABA Receptor	Cancer
Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC) .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-144724

HSP90-IN-10	HSP Apoptosis	Cancer
HSP90-IN-10 (Compound 16s) is a potent inhibitor of HSP90. HSP90-IN-10 exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC₅₀ value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .

HY-143582

ATX inhibitor 9	Others	Cancer
ATX inhibitor 9 is a potent inhibitor of ATX. ATX inhibitor 9 is a thickened heteroaryl derivatives compound. Autotaxin (ATX), also known as ENPP2, is a secreted enzyme that is highly expressed mainly in cancer cells, bronchial epithelial cells and alveolar macrophages in the lung. ATX inhibitor 9 has the potential for the research of cancer or fibrous degenerative disease (extracted from patent WO2021078227A1, compound 3) .

HY-N2098

Obtusifolin	NF-κB	Cancer
Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway . Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein .

HY-145268

SLEC-11	Others	Cancer
SLEC-11 acts as a potential synthetic lethal lead for the research of gastric cancer. AL-GDa62 shows EC₅₀ of 12.2 μM and 8.2 μM for isogenic mammary epithelial cells MCF10A-WT (wild-type) and MCF10A-CDH1 ^-/- .

HY-145269

AL-GDa62	Others	Cancer
AL-GDa62 acts as a potential synthetic lethal lead for the research of gastric cancer. AL-GDa62 shows EC₅₀ of 3.2 μM and 2 μM for isogenic mammary epithelial cells MCF10A-WT (wild-type) and MCF10A-CDH1 ^-/- .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-122965

Batatasin III	FAK Akt	Cancer
Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-100395

F16	Apoptosis	Cancer
F16 is a potent growth inhibitor of the *neu-overexpressing cells and also selectively inhibits proliferation of mammary epithelial* as well as a variety of mouse mammary tumor and human breast cancer cell lines.

HY-156512

DT-6	TGF-beta/Smad	Cancer
DT-6 is an effective TGF-β1 inhibitor. DT-6 inhibits M2 macrophage induced epithelial to mesenchymal transition and invasive migration of cancer cells. DT-6 can be used for cancer diseases research .

HY-152084

Anticancer agent 93	Others	Cancer
Anticancer agent 93 is a 4-Hydroxycoumarin derivative. Anticancer agent 93 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .

HY-152085

Anticancer agent 94	Others	Cancer
Anticancer agent 94 is a 4-Hydroxycoumarin derivative. Anticancer agent 94 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .

HY-P99589

Sotevtamab 16B5; AB-16B5	Apoptosis	Cancer
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .

HY-P99592

Solitomab AMG 110; MT110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and *anti-epithelial-cell-adhesion-molecule (EpCAM)* antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-156716

MASTL-IN-2	Others	Cancer
MASTL-IN-2 is an MASTL (microtubule-associated serine/threonine kinase-like) inhibitor. MASTL-IN-2 inhibits human epithelial MIA PaCa cancer cell proliferation with IC₅₀ of 2.8 nM .

HY-116392B

DL-threo-PDMP hydrochloride	Glucosylceramide Synthase (GCS)	Cancer
DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .

HY-162153

CYY292	FGFR	Cancer
CYY292 is an FGFR1 inhibitor that specifically targets the FGFR1/AKT/Snail pathway in GBM cells. CYY292 dose-dependently inhibits cancer cell proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration in vitro .

HY-149894

MC-1-F2	Biochemical Assay Reagents	Cancer
MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active AXL inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .

HY-151428

Antitumor agent-78	Ferroptosis Apoptosis Bcl-2 Family COX	Cancer
Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .

HY-151429

Antitumor agent-77	Apoptosis Ferroptosis Bcl-2 Family COX	Cancer
Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .

HY-163178

Bisabosqual A	Apoptosis Autophagy	Cancer
Bisabosqual A, a potent asparagine synthetase (ASNS) inhibitor, with an IC₅₀ of 10.7 μM. Bisabosqual A can covalently modify the K556 site of ASNS protein. Bisabosqual A promotes oxidative stress and apoptosis, while inhibiting autophagy, cell migration and epithelial-mesenchymal transition (EMT), impeding cancer cell development .

HY-153910

AGPS-IN-1	Others	Cancer
AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .

HY-160066

SYL3C aptamer sodium	Others	Cancer
SYL3C aptamer sodium is a DNA aptamer that targets the epithelial cell adhesion molecule (EpCAM) on the surface of cancer cells. SYL3C aptamer sodium targets multiple human cancer cell lines including MDA-MB-231, Kato III, HT-29, T47D and SW480. The Kd of SYL3C aptamer sodium against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III is 38 nM and 67 nM, respectively. SYL3C aptamer sodium provides stability, high binding affinity, and selectivity for targeted cancer therapy, cancer cell imaging, and circulating tumor cell detection .

HY-P1416

Foxy-5	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-124745

KY-05009	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-135023

5-trans-PGE2 5-trans Prostaglandin E2	Cytochrome P450 Prostaglandin Receptor	Cancer
5-trans-PGE2 (5-trans Prostaglandin E2) is the active isomer of PGE2 and a potent activator of aromatase. Supplements the process of paracrine signaling between epithelial cells (expressing high levels of PGE2) and surrounding stromal cells (expressing high levels of aromatase). This process is involved in the growth and development of breast cancer .

HY-P1416A

Foxy-5 TFA 3 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-138657

NCGC00378430	Phosphatase	Cancer
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model .

HY-149577

EBV lytic cycle inducer-1	EBV	Cancer
Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers .

HY-150596

CT1-3	Apoptosis Bcl-2 Family JNK	Cancer
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .

HY-153894

SRX3177	CDK Epigenetic Reader Domain PI3K	Cancer
SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC₅₀s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively. SRX3177 exerts broad cytotoxic activity against cancer cells, but acts friendly with normal epithelial cells .

HY-160218

HPK1-IN-42

MAP4K Cancer

HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC₅₀ 50 of 0.24 nM .

HPK1-IN-42	MAP4K	Cancer
HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC₅₀ 50 of 0.24 nM .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

HY-108692

Enterolactone	Apoptosis Endogenous Metabolite	Cancer
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

HY-W011209

N6-Isopentenyladenosine 1 Publications Verification Riboprine	Autophagy Endogenous Metabolite	Cancer
N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .

HY-148093

PM-81I	STAT	Inflammation/Immunology Cancer
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer ^[1].

HY-148096

STAT6-IN-1	STAT	Inflammation/Immunology Cancer
STAT6-IN-1 (compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC₅₀=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer .

HY-138071

8α-Tigloyloxyhirsutinolide 13-O-acetate 8αTGH	STAT Pyroptosis Apoptosis Reactive Oxygen Species c-Myc Bcl-2 Family TrxR	Cancer
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library	1883 Compounds compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Anti-Ovarian Cancer Compound Library

1883 Compounds compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L103

Anti-Colorectal Cancer Compound Library

1618 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1618 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L132

Chemokine Compound Library

146 compounds

Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system.

The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases.

MCE supplies a unique collection of 146 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.

Cat. No.	Product Name	Target	Research Area